Stock News

The first-line application is expected to be completed by year end; a separate monotherapy NDA has a Feb. 27, 2027 FDA target.

AstraZeneca or Daiichi Sankyo will sponsor the planned breast cancer study, with all three companies sharing trial costs and retaining drug rights.

The Oct. 1 filing attributes the joint termination to delayed closing and gives no figure for any termination payment.

Bezant targets at least 9,000 tonnes of plant throughput in October, with first saleable concentrate expected late in the month.

The estimate puts contained copper at 495,400 tonnes; the separate Selebi North resource calculation remains pending.

Northcliff says the Sept. 23-effective report makes no material change to August's results; it holds 88.5 per cent of the partnership that owns Sisson.

Gross margin reached about 48 per cent in the June half, while WISeQey shares are due to trade as WQEY on Oct. 5 after an ADS conversion.

The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.

The AUTUS pulmonary valve can later be widened by catheter; the FDA cited a 62-child study and flagged longer-term risks.

Facility A begins at 7.25 per cent and Facility B stays at 9.95 per cent under a Sept. 28 agreement backed by subsidiary assets.

A 1.21-metre section graded 30.46% antimony, while the 2025 feasibility study assigns the metal no revenue.

Shareholders approved the Armada combination Sept. 30, while Evernorth expects roughly US$300M of gross cash before expenses.

Japan approved use with gemcitabine and nab-paclitaxel; Novocure's Oct. 1 release gave no Japanese shipment or coverage date.

The Erwin, Tennessee, unit will make reactor fuel for the naval propulsion program, with work scheduled for completion in August 2027.

A small post hoc MRI subgroup improved after 72 weeks, while placebo comparisons came from other liver measures in the larger STEP UP dataset.

The uncontrolled Canadian trial enrolled 11 patients; seven were evaluable for pain, and validated data analysis remains underway.

A one-year biomarker analysis could support accelerated approval while the same study runs toward possible full approval.

Enerflex schedules deliveries to an unnamed North American developer from 2027 through 2028 and has authorized US$85M for systems facilities.

Lifted Made closed the Kenosha building sale Sept. 29 and used US$841,110 to repay all its outstanding bank debt.

The FCA approved a prospectus on Sept. 29; MORE starts with a £12 annual dividend per share and has an Oct. 9 retail deadline.

The monthly 200 mg dose beat placebo at Week 16; patients have already been dosed in two atopic dermatitis Phase 3 studies.

United says it believes it is entitled to an order instructing FDA to withdraw Yutrepia's approval; the parties have one week to propose a judgment.

Jabil expects US$17.55 core EPS and a 6.1 per cent core operating margin in fiscal 2027 after quarterly revenue rose year on year.

Two more rigs are planned for Candelaria in the second half of October as the company targets a first-quarter 2027 finish.

Yancoal will recognize its share of Kestrel's production, revenue and earnings from Oct. 1 and expects to dispatch a circular to shareholders by Nov. 23.

The Australian explorer is selling 625,000 depositary shares with matching warrants and expects the financing to close Oct. 2.

The company expects to begin first human testing of its HC74-based ADC in advanced solid tumours in the fourth quarter of 2026.

A second hole returned 70.41 metres at 1.16 grams per tonne gold, while deeper drilling continues beneath Red Hills.

Holders have until Oct. 23 to vote on one new share for five to 15 existing shares, nomination rules and incentive-plan entitlements.

The 12-year deal covers two planned data halls backed by a 65 MW utility agreement; prepayment amounts and opening date are undisclosed.

The Brazil mine's first doré sale fetched more than US$4,200 an ounce as Cabral targets commercial production in the fourth quarter.

The China extension followed 240 patients, with long-term safety as its primary aim, while Sagimet prepares a U.S. Phase 3 trial.

The French electrical supplier now aims for a 21%-22% adjusted operating margin and projects €3.9 billion in 2026 data centre sales.

The AIM technology company's June 30 cash stood at £467,979, while its renewed sports services contract carried no disclosed value.

The deepest extension hole reached 907.4 metres downhole; TomaGold will use geophysical surveys to select further drill targets.

Atlas showed 13.9 per cent complete clearance on the rival pill at week 16 as Takeda awaits an FDA action in early 2027.

The ASX explorer plans to map the Manna Hill and Waukaringa goldfields after licence grant and begin drilling in early 2027.

The Western Australian deposit also holds a 12.5-million-tonne iron resource; a study of potential economics is due in December.

A 350-patient Phase 3 study is testing PSMA PET with MRI before biopsy; Telix's Sept. 30 release gives no readout or NDA submission date.

Battle Green can require a share-funded note purchase, while Vireo can trigger one at a lower share price; the maturity route uses a future trading average.